Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Shiller on Molecular Diagnostics in Gastrointestinal Cancers

October 23rd 2018

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses molecular diagnostics in gastrointestinal (GI) cancers.

Sequencing Strategies, Combinations Mark Next Steps in HCC

October 23rd 2018

Josep M. Llovet, MD, PhD, discusses the rapidly evolving treatment landscape for hepatocellular carcinoma and the work that lies ahead.

Dr. Iqbal on Second- and Third-Line Therapies in Gastric Cancer

October 23rd 2018

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses second- and third-line therapies in gastric cancer.

Neoadjuvant Nivolumab Plus Ipilimumab Active in dMMR Early-Stage Colon Cancer

October 23rd 2018

First results from a study of neoadjuvant ipilimumab plus nivolumab in patients with early-stage colon cancer found a major pathologic response achieved in all 7 patients with mismatch repair deficient tumors.

Trifluridine/Tipiracil Extends Survival in Heavily Pretreated Gastric/GEJ Cancer

October 22nd 2018

Trifluridine/tipiracil reduces the risk of death by about one-third compared with placebo in patients with heavily pretreated gastric or gastroesophageal junction cancer.

Atezolizumab Plus Bevacizumab Shows Durable Activity in Advanced HCC

October 22nd 2018

The combination of the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab showed promising and durable antitumor activity in a phase Ib study of patients with advanced hepatocellular carcinoma.

Metastatic CRC: Moving Into the Future

October 22nd 2018

Precision Medicine Further Explored in Metastatic CRC

October 22nd 2018

Immunotherapy in MSS Colorectal Cancer

October 22nd 2018

Immunotherapy Regimens in dMMR/MSI-High Metastatic CRC

October 22nd 2018

Significance of MSI Status and TMB in Metastatic CRC

October 22nd 2018

Triplet Regimens in BRAF-Mutant Metastatic CRC

October 22nd 2018

Targeting BRAF in Metastatic CRC

October 22nd 2018

Tumor Sidedness in CRC: Distinguishing Factors

October 22nd 2018

Combination Strategies in Frontline Metastatic CRC

October 22nd 2018

RAS Status and Treatment Decisions in Metastatic CRC

October 22nd 2018

Recommendations for Molecular Testing in Metastatic CRC

October 22nd 2018

Current State of Molecular Testing for Metastatic CRC

October 22nd 2018

Entrectinib Active Across Multiple Tumor Types

October 22nd 2018

More than half of patients with advanced solid tumors associated with NTRK gene fusions responded to treatment with the small-molecule inhibitor entrectinib, an integrated analysis of 3 clinical trials showed.

Engineered Anti-MAGE-A T-Cells Show Early Promise

October 21st 2018

Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.